← Leaderboards
Fred R Hirsch
University Of Colorado Denver
$4,253,946
Attributed
$4,313,985
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2012–24$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$14,318,229 · 5
By mechanism
U54$11,383,272 · 4
U01$2,934,957 · 1
Top collaborators
- Adolfo Garcia-Sastre6 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Spero M Manson$45,709,705
- Dedra S Buchwald$63,799,088
- Roberta Pelanda$15,844,961
- Elizabeth J Shpall$12,617,686
- Lance U'ren$588,285
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungLungMalignant NeoplasmsBaseInstitutionAntibody ResponseCancer PatientTumorVaccinesSmokingAntibodies2019-NcovVaccinationInfectionHuman SubjectAdvocateGenderMorbidity - Disease RateProgramsData Science CoreDoctor Of PhilosophyBudgetsScienceCovid-19
Grant awards (14)
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses$599,601
U54 · FY2024 · CA · contact PI
Administrative Core$119,921
U54 · FY2024 · CA · contact PI
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses$3,271,928
U54 · FY2023 · CA · contact PI
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses$2,044,217
U54 · FY2022 · CA · contact PI
Administrative Core$458,807
U54 · FY2022 · CA · contact PI
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses$120,079
U54 · FY2022 · CA · contact PI
Admin-Core-001$120,079
U54 · FY2022 · CA · contact PI
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses$3,968,419
U54 · FY2020 · CA · contact PI
Administrative Core$680,221
U54 · FY2020 · CA · contact PI
Squamous Cell Carcinoma of the Lung: Validation of Molecular Signatures for Progn$596,174
U01 · FY2016 · CA · contact PI
Squamous Cell Carcinoma of the Lung: Validation of Molecular Signatures for Progn$597,111
U01 · FY2015 · CA · contact PI
Squamous Cell Carcinoma of the Lung: Validation of Molecular Signatures for Progn$580,661
U01 · FY2014 · CA · contact PI
Squamous Cell Carcinoma of the Lung: Validation of Molecular Signatures for Progn$561,038
U01 · FY2013 · CA · contact PI
Squamous Cell Carcinoma of the Lung: Validation of Molecular Signatures for Progn$599,973
U01 · FY2012 · CA · contact PI